COVID-19 Oral Vaccine


Phase 1 trial

Exp Date

December 2020 (Est)

Amp Volatility Score

Catalyst Info & Data Links


  • Our vaccine platform is a replication-defective adenovirus type-5 vectored vaccine that expresses antigen along with a novel toll-like receptor 3 agonist as an adjuvant. These vaccines have been well tolerated, and able to generate robust humoral and cellular immune responses to the expressed antigens

Updated by HC


Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See What The Community Is Saying - Click To See Full Post

Small Cap COVID-19 Vaccine Pla...

Based on our research and analysis, some interesting small cap COVID-19 Vaccine players that are traded on U.S. markets are ARCT, INO, ALT and VXRT. These four appear to have clinical trial data reado...

VXRT - FDA Clearance of IND Ap...

#VXRT announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon